<SEC-DOCUMENT>0001104659-25-022615.txt : 20250311
<SEC-HEADER>0001104659-25-022615.hdr.sgml : 20250311
<ACCEPTANCE-DATETIME>20250311171703
ACCESSION NUMBER:		0001104659-25-022615
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250308
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250311
DATE AS OF CHANGE:		20250311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		25728759

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>tm258886d1_8ka.htm
<DESCRIPTION>FORM 8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ptgx="http://protagonist-inc.com/20250308">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_ptgx_protagonist%2Dinc.com_20250308 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20250308_20250308 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001377121 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001377121</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgx-20250308.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001377121</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-08</xbrli:startDate>
        <xbrli:endDate>2025-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0; text-indent: 1.5in">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><p style="margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20250308__20250308_zuMfYvYvn9I4"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000009" name="dei:DocumentType">8-K/A</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 12pt"><b>CURRENT REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Pursuant to Section
13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>of the Securities
Exchange Act of 1934</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <b>March 11, 2025 (<span id="xdx_909_edei--DocumentPeriodEndDate_c20250308__20250308_zOVhqsUqyjPe"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 8,
2025</ix:nonNumeric></span></b><b>)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20250308__20250308_z1ztYjyCHlO"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000011" name="dei:EntityRegistrantName">PROTAGONIST THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250308__20250308_zyNTWN8twW6g"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityFileNumber_c20250308__20250308_zTX4QUYNTea3"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000013" name="dei:EntityFileNumber">001-37852</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20250308__20250308_zdzP67S4ZbHk"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-0505495</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br/>
File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/>
Identification No.)</span></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Protagonist Therapeutics,&#160;Inc.</b><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250308__20250308_zJwI5u8Kulve"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000015" name="dei:EntityAddressAddressLine1">7707 Gateway Blvd.</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20250308__20250308_zWFkTyhWYM05"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 140</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20250308__20250308_zAbOTYHSmDtf"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000017" name="dei:EntityAddressCityOrTown">Newark</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20250308__20250308_zpgB4qbTzxi5"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20250308__20250308_zDl9pmKZY2Zb"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">94560-1160</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20250308__20250308_zRs9B6tUUEQ3"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000020" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20250308__20250308_zDoybjupvCid"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000021" name="dei:LocalPhoneNumber">474-0170</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90C_edei--WrittenCommunications_c20250308__20250308_zEoKAgMFv0xl"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20250308__20250308_zVDShNKCEPS"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_905_edei--PreCommencementTenderOffer_c20250308__20250308_zvxU0u6I5Jl5"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
    <td style="width: 2%; text-align: left"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20250308__20250308_zlGPXAin1b0b"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: justify; width: 98%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 35%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 28%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 35%; font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which<br/>
registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--Security12bTitle_c20250308__20250308_zo9ac1tIR7Ee"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.00001</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--TradingSymbol_c20250308__20250308_zkL0j68Prvs6"><ix:nonNumeric contextRef="AsOf2025-03-08" id="Fact000027" name="dei:TradingSymbol">PTGX</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font-size: 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SecurityExchangeName_c20250308__20250308_zJuwx3bIgWZj"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Emerging growth company </span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20250308__20250308_zAvipMAkxvI6"><ix:nonNumeric contextRef="AsOf2025-03-08" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Explanatory Note</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-weight: normal">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-weight: normal">This
Form&#160;8-K/A&#160;amends the Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on March 10, 2025. The
purpose of this amendment is to replace the press release announcing top line results from the Phase 2b ANTHEM-UC study of icotrokinra
in patients with ulcerative colitis previously filed as Exhibit 99.2 with the version attached to this Form&#160;8-K/A&#160;as Exhibit
99.2, which contains a clerical revision to the &#8220;p&#8221; value previously reported for clinical remission at week 12 from p&lt;0.001
to p&lt;0.01. Effective upon the filing of this Form&#160;8-K/A, Exhibit 99.2 of the March 10, 2025 Form&#160;8-K is replaced and superseded
in its entirety by Exhibit 99.2 to this Form&#160;8-K/A</span>.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Item 8.01. Other Information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On March 8, 2025, Protagonist Therapeutics, Inc. (the &#8220;Company&#8221;)
issued a press release announcing that icotrokinra clinical study results demonstrate its potential to shift treatment paradigm and set
a new standard for treatment in plaque psoriasis. A copy of the press release titled &#8220;Icotrokinra Clinical Study Results Demonstrate
its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis&#8221; is attached hereto as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">On March 10, 2025, the Company issued a press release
announcing top line results from the Phase 2b ANTHEM-UC study of icotrokinra in patients with ulcerative colitis. A copy of the press
release titled &#8220;Protagonist Reports Positive Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform
the Treatment Paradigm for Patients with Ulcerative Colitis&#8221; is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K
and is incorporated by reference herein. In addition, an updated corporate presentation is available on the Company&#8217;s website at
www.protagonist-inc.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Item 9.01 Financial Statements and Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 66.45pt"><a href="tm258886d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><a href="tm258886d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated March 8, 2025,
                   titled &#8220;Icotrokinra Clinical Study Results Demonstrate its Potential to Shift Treatment Paradigm and Set a New
                   Standard for Treatment in Plaque Psoriasis&#8221;.</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 66.45pt"><a href="tm258886d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><a href="tm258886d1_ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated March 10, 2025,
                   titled &#8220;Protagonist Reports Positive Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to
                   Transform the Treatment Paradigm for Patients with Ulcerative Colitis&#8221; (as corrected).</span></a></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">Cover Page
Interactive Data File (embedded within the Inline XBRL document).</td></tr>
                                                                                                                                </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 339.5pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 20.7pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><b>Protagonist Therapeutics, Inc.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Dated: March 11, 2025</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Asif Ali</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</td></tr>
  </table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVEKwjAQRE/QOyz5LpoGFeynRUWsIkXE32BXCbbZsonaHslbGlvEZWFZZt6MELFY08pUyHBeFDkcsW4q7REKvCKjvWBwZJttCuEWeDPOs7a+f39gRoHBwExHSukg9NancVimIKdjORurCch5Kudw2Inoq2dkr6ZE642uQNsSDkwNG/SauyHhqFuyVHd91QnZGbIpJCM5yG9QMlGwp6d+Ed8d5HkmorifSKyZHk1wLVuP9kvCssI61LmB/m/0AQuDSpU= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm258886d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm258886d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Icotrokinra Clinical Study Results Demonstrate
its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Nearly half of patients with moderate-to-severe
plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Topline results from Phase 3 ICONIC-ADVANCE
1&amp;2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsO</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Results pave the way to initiate the first-ever
head-to-head study (ICONIC-ASCEND) seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe
PsO</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEWARK,
Calif.,&nbsp;March&nbsp;8, 2025&nbsp;&ndash;&nbsp;</B></FONT>Protagonist Therapeutics,&nbsp;Inc. (&ldquo;Protagonist&rdquo; or the &ldquo;Company&rdquo;)<FONT STYLE="background-color: white">&nbsp;</FONT>today
announced new icotrokinra (JNJ-2113) data from the comprehensive Phase 3 clinical program and the planned initiation of the first-ever
head-to-head study in plaque psoriasis (PsO) seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable
biologic, ustekinumab. Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor
and is being studied in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Data from the Phase 3 ICONIC-LEAD<SUP>a</SUP>
study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, show once daily icotrokinra
demonstrated significant skin clearance and a favorable safety profile in adults and adolescents 12 years of age and older with moderate-to-severe
plaque PsO.<SUP>i</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Key findings from the ICONIC-LEAD
study:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>At
                                            Week 24, nearly half of patients treated with icotrokinra achieved completely clear skin
                                            &ndash; 46% reached IGA 0 and 40% reached PASI 100.<SUP>i</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Nearly
                                            two-thirds (65%) of patients treated with once daily icotrokinra achieved an Investigator&rsquo;s
                                            Global Assessment (IGA)<SUP>b</SUP> score of 0/1 (clear or almost clear skin) and 50% achieved
                                            a Psoriasis Area and Severity Index (PASI)<SUP>c </SUP>90 response, compared to 8% and 4%
                                            receiving placebo, respectively (P&lt;0.001 for both endpoints) at Week 16.<SUP>i</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Continued
                                            skin clearance improvement was reported at Week 24 with 74% of patients treated with icotrokinra
                                            achieving IGA 0/1 and 65% achieving PASI 90.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Similar
                                            proportions of patients experienced adverse events (AEs) between icotrokinra (49%) and placebo
                                            groups (49%), with no new safety signals identified.<SUP>i</SUP></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Results from a subgroup analysis of the ICONIC-LEAD
study evaluating icotrokinra in the adolescent population will be presented at a forthcoming medical meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Additionally, topline results from
the icotrokinra versus deucravacitinib Phase 3 ICONIC-ADVANCE 1&amp;2<SUP>d </SUP>studies are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The
                                            study met its co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>The
                                            study also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to
                                            deucravacitinib in patients with moderate-to-severe plaque PsO.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ii,iii</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the positive outcomes of the ADVANCE 1&amp;2 studies, our
partner Johnson&nbsp;&amp; Johnson is initiating the Phase 3 ICONIC-ASCEND<SUP>e</SUP> study, the first-ever head-to-head study seeking
to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
new results from the superiority ICONIC-ADVANCE 1&amp;2 studies involving head-to-head comparison with the oral therapeutic deucravacitinib,
combined with the results from the ICONIC-LEAD study, reinforce </FONT>icotrokinra&rsquo;s potential as a paradigm shifting, highly effective
first- and only-in-class targeted oral IL-23 receptor antagonist for treatment of psoriasis,&rdquo; said&nbsp;Dinesh V. Patel, Ph.D.,
President and Chief Executive Officer at Protagonist. &ldquo;Icotrokinra offers a standout combination of complete skin clearance and
favorable safety profile in a once-daily pill and continues to establish itself as a potential first-line systemic therapy for psoriasis.
We&rsquo;re very excited about the continued expansion of the ICONIC clinical development program, as exemplified by the initiation of
the phase 3 ICONIC-ASCEND superiority study of icotrokinra versus ustekinumab<FONT STYLE="font-size: 10pt">.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Editor&rsquo;s notes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
</FONT>ICONIC-LEAD is a Phase 3 randomized controlled trial (RCT) evaluating the efficacy and safety of icotrokinra compared with placebo
in 684 participants (icotrokinra=456; placebo=228) 12 years of age or older with moderate-to-severe plaque PsO, with the higher efficacy
bar of PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints. ICONIC-LEAD enrolled 66 adolescent patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">b. The IGA is a five-point scale with a severity
score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate and 4 indicates severe disease.<SUP>iv</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">c. The PASI score grades the amount of surface
area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness.<SUP>v
</SUP>PASI 90 corresponds to an improvement of &gt;=90% in PASI score from baseline.<SUP>v</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
ICONIC- ADVANCE 1&nbsp;&amp; 2 are Phase 3 RCTs evaluating the efficacy and safety of icotrokinra compared with placebo and deucravacitinib
in participants with </FONT>moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary
endpoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.
ICONIC-ASCEND is a Phase 3 RCT and the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, i</FONT>cotrokinra,
compared to an injectable biologic, ustekinumab in moderate-to-severe plaque PsO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the ICONIC Clinical Development Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The pivotal Phase 3 ICONIC clinical development
program of icotrokinra (JNJ-2113) in adult and adolescent individuals with moderate-to-severe plaque PsO was initiated with two studies
in Q4 2023 &ndash; ICONIC-LEAD and ICONIC-TOTAL &ndash; pursuant to the license and collaboration agreement between Protagonist Therapeutics,&nbsp;Inc.
and Janssen Biotech,&nbsp;Inc., a Johnson&nbsp;&amp; Johson company.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>vi
</SUP></FONT>The ICONIC clinical development program is being conducted by Johnson and Johnson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICONIC-LEAD
(</FONT><U>NCT06095115</U>) is a randomized controlled trial (RCT) to evaluate the efficacy and safety of icotrokinra compared with placebo
in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary
endpoints.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>vii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICONIC-TOTAL
(</FONT><U>NCT06095102</U>) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of PsO
in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA
score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>viii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Phase 3 studies in the development program include ICONIC-ADVANCE 1 (</FONT><U>NCT06143878</U>) and ICONIC-ADVANCE 2 (<U>NCT06220604</U>),
which are evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe
plaque PsO.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ix</SUP></FONT><SUP>,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</FONT></SUP>&nbsp;ICONIC-ASCEND
will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque
psoriasis. ICONIC-PsA 2 (<U>NCT06807424</U>) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants
with active psoriatic arthritis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Plaque Psoriasis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Plaque psoriasis (PsO) is a chronic immune-mediated
disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xi
</SUP></FONT>It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xii
</SUP></FONT>Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe. <SUP>xi </SUP>On Caucasian
skin, plaques typically appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xiii
</SUP></FONT>On skin of color, the plaques may appear darker and thicker and more of a purple, gray or dark brown color.<SUP>xii</SUP>
Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows and torso.<SUP>xii </SUP>Living
with plaque PsO can be a challenge and impact life beyond a person&rsquo;s physical health, including emotional health, relationships,
and handling the stressors of life.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xiv</SUP></FONT> Psoriasis
on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact
on quality of life.<SUP>xii,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">xv</FONT></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Icotrokinra (JNJ-77242113, JNJ-2113)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Investigational icotrokinra is the first targeted
oral peptide designed to selectively block the IL-23 receptor.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xvi
</SUP></FONT>The IL-23 pathway underpins the inflammatory response in moderate-to-severe plaque psoriasis (PsO), ulcerative colitis (UC)
and other diseases.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xvii,xviii</SUP></FONT>&nbsp;Icotrokinra
binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in
human T cells.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xix</SUP></FONT> The license and collaboration
agreement established between Protagonist Therapeutics,&nbsp;Inc. and Janssen Biotech,&nbsp;Inc., a Johnson&nbsp;&amp; Johnson company,
in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xx</SUP></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Icotrokinra was jointly discovered and is being developed pursuant
to the license and collaboration agreement between Protagonist and Johnson&nbsp;&amp; Johnson. Johnson&nbsp;&amp; Johnson retains exclusive
worldwide rights to develop icotrokinra in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research
conducted pursuant to the agreement against a broad range of indications.<SUP>xxi,xxii,xxiii</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical
development program in moderate-to-severe plaque PsO and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in moderately to
severely active UC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>About Protagonist</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Protagonist Therapeutics is a discovery through
late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist&rsquo;s proprietary
discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected
in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23
receptor (&ldquo;IL-23R&rdquo;) which is licensed to Johnson&nbsp;&amp; Johnson Innovative Medicines (&ldquo;JNJ&rdquo;), formerly Janssen
Biotech,&nbsp;Inc. Following icotrokinra&rsquo;s joint discovery by Protagonist and JNJ scientists pursuant to the companies&rsquo; IL-23R
collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility
for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for
the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals
pursuant to a worldwide collaboration and license agreement entered into in 2024, under which the Company remains primarily responsible
for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically
and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity
program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company&rsquo;s website at <U>www.protagonist-inc.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note on Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements
regarding the potential of icotrokinra to shift the psoriasis treatment paradigm. In some cases, you can identify these statements by
forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including,
but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our
collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and
compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual
property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can
be found in our periodic filings with the Securities and Exchange Commission, including under the heading &ldquo;Risk Factors&rdquo;
contained in our most recently filed periodic reports on Form&nbsp;10-K and Form&nbsp;10-Q filed with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity,
and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after
the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corey
Davis, Ph.D.<BR>
LifeSci Advisors<BR>
+1 212 915 2577<BR>
</FONT><U>cdavis@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Virginia Amann, Founder/CEO&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
833 500 0061 ext 1<BR>
ENTENTE Network of Companies<BR>
</FONT><U>virginiaamann@ententeinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>i</SUP> Bissonnette, R et al. Icotrokinra, a Targeted Oral Peptide
That Selectively Blocks the Interleukin-23&ndash;Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through
Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial. Late-breaking research presentation (Abstract
#66708) at the American Academy of Dermatology (AAD) 2024 Annual Meeting. March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>ii</SUP> Data on file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>iii</SUP> Data on file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>iv</SUP> Simpson E, Bissonnette R, Eichenfield LF, et al. The
validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD&trade;): The development and reliability testing of a novel clinical
outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>v</SUP> Thompson Jr, D. How the Psoriasis Area and Severity Index
works. Everyday Health. Available at:&nbsp;<U>https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works</U>. Accessed
March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>vi</SUP> Protagonist Therapeutics. Press release. Protagonist
announces advancement of JNJ-2113 across multiple indications. Available at: https://www.accesswire.com/791174/protagonist-announces-advancement-of-jnj-2113-across-multiple-indications.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>vii</SUP> Clinicaltrials.gov. A study of JNJ-2113 in adolescent
and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>viii</SUP> Clinicaltrials.gov. A study of JNJ-2113 for the treatment
of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL).
Identifier NCT06095102. https://classic.clinicaltrials.gov/ct2/show/NCT06095102. Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>ix</SUP> Clinicaltrials.gov. A Study of JNJ-77242113 for the
Treatment of Participants With Moderate to Severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&amp;rank=10.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>x</SUP> Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment
of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. https://clinicaltrials.gov/study/NCT06220604.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xi</SUP> National Psoriasis Foundation. About Psoriasis. Available
at: https://www.psoriasis.org/about-psoriasis. Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xii</SUP> National Psoriasis Foundation. Psoriasis Statistics.
Available at: https://www.psoriasis.org/content/statistics. Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xiii</SUP> National Psoriasis Foundation. Plaque Psoriasis. Available
at: https://www.psoriasis.org/plaque/.Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xiv</SUP> National Psoriasis Foundation. Life with Psoriasis.
Available at: https://www.psoriasis.org/life-with-psoriasis/. Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xv</SUP> National Psoriasis Foundation. High Impact Sites. Available
at: <U>https://www.psoriasis.org/high-impact-sites/</U>. Accessed Sep March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xvi</SUP> Bissonnette R, et al. Data presentation. A phase 2,
randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER
1. Presented at WCD 2023, July 3-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xvii</SUP> Razawy W, et al. The role of IL-23 receptor signaling
in inflammation-mediated erosive autoimmune arthritis and bone remodeling.&nbsp;<I>Eur J Immunol</I>. 2018 Feb; 48(2): 220&ndash;229.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xviii</SUP> Tang C, et al. Interleukin-23: as a drug target for
autoimmune inflammatory diseases.&nbsp;<I>Immunology</I>. 2012 Feb; 135(2): 112&ndash;124.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xix</SUP> Pinter A, et al. Data Presentation. JNJ-77242113 Treatment
Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the
Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xx</SUP> Johnson &amp; Johnson. Press release. Janssen enters
into worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. for the oral Interlukin-23 receptor
antagonist drug candidate for the treatment of Inflammatory Bowel Disease. Available at: https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-exclusive-license-and-collaboration-agreement-with-protagonist-therapeutics-inc-for-the-oral-interlukin-23-receptor-antagonist-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xxi</SUP> Protagonist Therapeutics. Press release. Protagonist
Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists.
Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xxii</SUP> Protagonist Therapeutics. Press release. Protagonist
Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xxiii</SUP> Protagonist Therapeutics. Press release. Protagonist
Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235)
in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-<FONT STYLE="font-size: 10pt">301764181</FONT>.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm258886d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm258886d1_ex99-2img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Protagonist Reports Positive
Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative
Colitis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Clinical response rate
of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>All three doses met the primary endpoint of
clinical response at Week 12, with a favorable safety profile</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>These results in ulcerative colitis build on
strong data&nbsp;recently reported&nbsp;for the plaque psoriasis&nbsp;Phase 3&nbsp;program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEWARK,
Calif.,&nbsp;March&nbsp;10, 2025&nbsp;&ndash;&nbsp;</B></FONT>Protagonist Therapeutics,&nbsp;Inc. (&ldquo;Protagonist&rdquo; or the &ldquo;Company&rdquo;)<FONT STYLE="background-color: white">&nbsp;</FONT>today
announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral
peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). The study conducted
by Protagonist&rsquo;s collaboration partner, Johnson&nbsp;&amp; Johnson, met its primary endpoint of clinical response<SUP>a</SUP> in
all icotrokinra dose groups evaluated. Additionally, the study demonstrated clinically meaningful differences versus placebo in key secondary
endpoints of clinical remission<SUP>b</SUP>, symptomatic remission and endoscopic improvement at Week 12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Key findings from the ANTHEM-UC study
(n=252) are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>All
                                            three doses of once daily icotrokinra met the primary endpoint of clinical response at Week
                                            12.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>A
                                            response rate of 63.5% for patients treated with the highest dose of icotrokinra was achieved
                                            at Week 12 versus 27.0% for placebo (p&lt;0.001).</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>30.2%
                                            of patients treated with the highest dose of icotrokinra demonstrated clinical remission
                                            at Week 12 versus 11.1% of patients who received placebo (p&lt;0.01).</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>Clinical
                                            remission and response rates continued to improve through Week 28.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>i</SUP></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Icotrokinra
was well tolerated with the </FONT>proportions of participants reporting one or more adverse events (AEs) being similar between the icotrokinra
dose groups and the placebo group.<SUP>i</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT>We
are thrilled with the impressive results of once daily oral icotrokinra in the ANTHEM Phase 2 ulcerative colitis study, broadening the
potential utility of this first-in-class and only-in-class oral IL-23 receptor antagonist from psoriasis to inflammatory bowel diseases,&rdquo;
said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. &ldquo;This is another example of Protagonist&rsquo;s
oral peptide platform delivering transformative, paradigm shifting outcomes in the hands of a world-leading development partner. Icotrokinra
has the potential to transform the treatment landscape in UC through its distinctive profile of efficacy, safety, tolerability, and convenience
of a once-daily oral treatment. We eagerly await icotrokinra&rsquo;s further progression into more advanced clinical studies in ulcerative
colitis and Crohn&rsquo;s disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Comprehensive results from the ANTHEM-UC
study are being prepared for presentation at upcoming medical congresses by our partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Editor&rsquo;s notes:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Clinical response is defined as decrease from baseline in the modified
                                            Mayo score by greater than or equal to (&gt;=) 30 percent (%) and &gt;=2 points, with either
                                            a &gt;=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding
                                            subscore of 0 or 1.</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Clinical remission is defined as a Mayo stool frequency subscore
                                            of 0 or 1 and not increased from induction baseline, a Mayo rectal bleeding subscore of 0,
                                            and a Mayo endoscopy subscore of 0 or 1 with no friability present on the endoscopy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>About ANTHEM-UC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANTHEM-UC
(</FONT><U>NCT06049017</U>) is a Phase 2b multicenter, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and
safety of icotrokinra (JNJ-77242113, JNJ-2113) in patients with moderately to severely active ulcerative colitis who had an inadequate
response or intolerance to conventional therapy (e.g., thiopurines or corticosteroids), prior biologics (TNF antagonists or vedolizumab)
and/or ozanimod or approved JAK inhibitors. The study is evaluating three once-daily dosages of &NegativeThickSpace;icotrokinra
taken orally.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Ulcerative Colitis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Ulcerative colitis (UC) is
a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny
open sores, or ulcers, that produce pus and mucus. It is the result of the immune system&rsquo;s overactive response. <SUP>&nbsp;</SUP>Symptoms
vary but may typically include loose and more urgent bowel movements, rectal bleeding or bloody stool, persistent diarrhea, abdominal
pain, loss of appetite, weight loss, and fatigue.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>iii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Icotrokinra (JNJ-77242113, JNJ-2113)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Investigational icotrokinra
is the first targeted oral peptide designed to selectively block the IL-23 receptor,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>iv
</SUP></FONT>which underpins the inflammatory response in moderate-to-severe plaque psoriasis, ulcerative colitis and offers potential
in other IL-23-mediated diseases.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>v</SUP></FONT><SUP>,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi</FONT></SUP>&nbsp;Icotrokinra
binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in
human T cells.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>vii</SUP></FONT>&nbsp;The license and collaboration
agreement established between Protagonist Therapeutics,&nbsp;Inc. and Janssen Biotech,&nbsp;Inc., a Johnson&nbsp;&amp; Johnson company,
in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>viii</SUP></FONT>&nbsp;Icotrokinra
was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and&nbsp;Johnson&nbsp;&amp;
Johnson.&nbsp;Johnson&nbsp;&amp; Johnson&nbsp;retains exclusive worldwide rights to develop icotrokinra in Phase 2 clinical trials and
beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ix</SUP></FONT><SUP>,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">x</FONT>,<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">xi</FONT></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Icotrokinra is being studied
in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque psoriasis and active psoriatic arthritis and
the Phase 2b ANTHEM-UC study in moderately to severely active ulcerative colitis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>About Protagonist</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protagonist
Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide,
derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application
submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively
blocks the Interleukin-23 receptor (&ldquo;IL-23R&rdquo;) which is licensed to Janssen Biotech,&nbsp;Inc., </FONT>a Johnson&nbsp;&amp;
Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson&nbsp;&amp; Johnson scientists pursuant to the companies'
IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson&nbsp;&amp; Johnson
assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in
Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized
with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company
remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery
programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin
program, and an oral obesity program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at&nbsp;<U>www.protagonist-inc.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cautionary Note on Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements
regarding the potential benefits of icotrokinra, and expectations regarding the icotrokinra development program. In some cases, you can
identify these statements by forward-looking words such as &quot;anticipate,&quot; &quot;believe,&quot; &quot;may,&quot; &quot;will,&quot;
 &quot;expect,&quot; or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those
anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone
payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of
product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately
protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting
our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading &quot;Risk
Factors&quot; contained in our most recently filed periodic reports on Form&nbsp;10-K and Form&nbsp;10-Q filed with the Securities and
Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial
condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements
contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events
or otherwise, after the date of this press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corey
Davis, Ph.D.<BR>
LifeSci Advisors<BR>
+1 212 915 2577<BR>
</FONT><U>cdavis@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Virginia Amann, Founder/CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
833 500 0061 ext 1<BR>
ENTENTE Network of Companies<BR>
</FONT><U>virginiaamann@ententeinc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>i
</SUP></FONT>Data on file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ii
</SUP></FONT>Clinicaltrials.gov. A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC).
Identifier NCT06049017. https://clinicaltrials.gov/study/NCT06049017?term=ANTHEM-UC&amp;rank=1. Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>iii
</SUP></FONT>Crohn&rsquo;s &amp; Colitis Foundation. What is ulcerative colitis? Available at: https://www.crohnscolitisfoundation.org/what-is-ulcerative-colitis.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>iv
</SUP></FONT>Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113
for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>v
</SUP></FONT>Razawy W, et al. The role of IL<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>23 receptor signaling in
inflammation<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>mediated erosive autoimmune arthritis and bone remodeling.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><I>Eur
J Immunol</I>. 2018 Feb; 48(2): 220&ndash;229.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>vi
</SUP></FONT>Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases.&nbsp;<I>Immunology</I>. 2012 Feb;
135(2): 112&ndash;124.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>vii
</SUP></FONT>Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo
in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>viii
</SUP></FONT>Johnson &amp; Johnson. Press release. Janssen enters into worldwide exclusive license and collaboration agreement with Protagonist
Therapeutics, Inc. for the oral Interlukin-23 receptor antagonist drug candidate for the treatment of Inflammatory Bowel Disease. Available
at: https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-exclusive-license-and-collaboration-agreement-with-protagonist-therapeutics-inc-for-the-oral-interlukin-23-receptor-antagonist-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>ix
</SUP></FONT>Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech
for the continued development and commercialization of IL-23 antagonists. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>x
</SUP></FONT>Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral
Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>xi
</SUP></FONT>Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER
1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-301764181.html.
Accessed March 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ptgx-20250308.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6PabOdzZR+GYkxtmB1bRm67ygh2paM1y9j3p628asC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ptgx="http://protagonist-inc.com/20250308" elementFormDefault="qualified" targetNamespace="http://protagonist-inc.com/20250308">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://protagonist-inc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20250308_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgx-20250308_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ptgx-20250308_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ptgx-20250308_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://protagonist-inc.com/role/Cover" xlink:href="ptgx-20250308.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://protagonist-inc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm258886d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm258886d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  /8# 2(  A$! Q$!_\0
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M=EIFC^&/'T>N:I<3+J-R-02/Q!K'A?1_"INEALE\0KJ<]EHEY^S_ ,=?C_\
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M)XHUBSM;J_M/#_AG1_$.M7.C65[K-MIATW3M5O+#\1X/^#B?Q;X@M[#Q_P"
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M?A;X@>$7U[3H8[C5-%77O"U[JEB==TM9(WOM+^W">TL;FSN9XMTX(_-O4/\
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M49WNFY\Y_%%_P<*_''XA?LU?\%IO^"2'QZ^%'P"\;?M1_$7X9_##XO:]X7^
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MQU?7-)T2TU'7/%Y^(7C'5?'GB;5?!.L^&=%\-7?P3\-?V'/A=^VE_P '7/\
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MX,@D(D:06\[M\ Y8[0#<)(UB%O=0K%<V=EM-LQ"M)D. ?T<_MY_![X;?&/\
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MK6NHVFDR:)ICGQ-)\+=<^-\?B7Q/I=U?^'9[&Q@@T2+UW_@EK^U1\9?V2O\
M@WK_ &"?B?\ !7]DGXK_ +95]_:OCWPWXG^&?P/GTM?'7A7X?R?M _&^?QKX
M^L=!DGU'6_&.NZ!:6D1\/>%/#.DW-_J%]K=E<Z_?:+H]K>:]I?O/BW_@XZ_X
M(P^-/A5XL\)?&+QOX]TC4M;TO5]&\9?LJ?%G]E+XR3^.]:NC IO/A[J_@^V\
M%>(/A=J%]J]Y'+I&I:%J?CIM!75KR6XUK5])T^6]NZF2E%V4925K\T5>*UM9
MW:=_D3S+F4;.[6_3^OD?N9^SO\9?V??VAOA?X4^+G[-OC+P/X_\ A)XVCN_$
M'AK7_ DD4NE3:K=W;W>OO<VD$<,^A>)]/U2]N['Q/I>M6&A^)_#>MO<Z1XAT
MVVOKJ""+^>C_ (,]HHY/^"1ER67[G[4_QD4!"8UP?#WPW9@RQE5<.SDR!PWF
M;8_,W>5%LZC_ (-?/V5?CW^S5^QQ\;M6^+WPV\:? 3PY\;?VF/$/Q+^"WP%\
M>I,NN^ _AM)X=T#3;#5-1TW5I9/$.EZGXDN-NA3?\)#='Q%?:+X2T35+K3XK
MO6)]7UC\R/\ @BA_P4T_9O\ ^"*_[/?QF_X)W?\ !1R?XC_LV?M&_#'X]_$+
MQ?H?AS4?A%\3/&NG?%W1/&FD^&[/PKK'PWU#P5X2\0"_L-:O?"FI6>CWNJ#2
M_"^H6%YX<U?2O&'B)M>N;/0 TE'E:3:=U?3^MS^ZZ.SMHG,D<*([*58KD!@2
M&^9<[6(8,REE)1I)F4AIYC(5Q/PX\=6?Q*\$^$O'VC0:C:Z/XW\+>'_%^C6.
MM:=-HVOV6E>(M,@U:R@US1;S%SI>HQP7D45Q:S2L\<D3*41E<N4$GQ[^WO\
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MQL^:KB(PE3BFK22BY.#=X?!?A+XI?M>^(-6\+>'KW]FS2_ :1W<;^/O&NO\
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@C*]3$XF"E7K2<ZK5.-5.;UE:>(<ZS5V[>TG*274__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm258886d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm258886d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" /(# 2(  A$! Q$!_\0
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MT1;B6&WMO[7\2>)K[3-&T[[3<W5E;6WVR]A^T7.I:5;0^9/JNG1W/Q/\+O\
M@L/_ ,$Q_C5XT3X>_#']M[]G+Q3XRGN38V'AR'XE:'IVJZWJ)U"+2K?3/#-M
MK,VG'Q3JFIWUQ;V^AZ9X<_M2_P!?:>)]%M[^)U<@'Z5%E!VD\D9Q@GCD=0,=
MO\Y%.K&OM;TK2]/N]5OKZRLM-L+>>[O]1N[J&"PL;2VMI+VYNKR]D=;>UMK>
MSB:[GN)Y4ABM\3.ZQLC-\CZM_P %$_V%-%^#]S^T'?\ [8/[,[_ NTUO4?#$
MGQ=TOXY_#75_AY)XITF"SN-1\)VGBG2?$E]I.H>++2/4M.$GABPNKG73)J.G
MP1Z>]Q>VL4H!]H;AG&<?4$?S%>>^/?BO\,_A='IT_P 2/'W@KP';ZNT\>EW/
MC/Q3H?AB#49K7R3<P6,VMWME'=SPK<0R200-)*L;F39Y:2,OS+^S=_P4<_8:
M_:^U?4/#O[-'[47P8^,?BC21*^J>#/"GCG2)?']C;P200SZA/X!OI[/QDFCQ
M2W4,3ZT-#.D++YT7VP/;W B^5O\ @KS^R'_P3=_:[^&WPATG_@H_\4_#_P *
M?A]X3^(%P?ACJ_B?XXZ-\"=*USX@>*]#G4Z-I_B#7-5TBV\2:M/H6B7EW;:)
MIUU>7C0VUQ<I;!;>1U /U\L[J&\@6> _NVQC(*L"55BLB,%>*1=P62*14EB<
M-'(BNK*+5>4^*OBE\//A1X+UWQW\3O&GA'X>^!O#-O>:MXI\:>-/%&E^&_!O
MA>RC=Y+_ %'7O%?B*;3=(T;3Q<$W$EUK%Y:1V[:CI]O,T,M]8V\OR/\ !S_@
MK#_P3<_:!\='X9?!W]M3]G#QS\09=3&CZ7X.TWXI>&+3Q!XGU$R740M_!.G:
MM=Z?/X['FV<\?G^#5UVW$@B0R[KBW$H!^A;RQQE5=U#/N")G+R%5+,(T&7<J
MH+$(K$*"2,"E5U?.TYVG#<$$$J&P00"#A@2#R,X.""*_G:_X.0?VU/"O[/7_
M  3=_:*\*?#W]JO1O@/^U]J.B_ KQ5\(_!_@_P".-A\,_P!HS4O#$O[3/PVT
MGQ=XF\"^$M(U[2?B)KOAJ7PG9>-[/Q#J&F:?>:./#VD>+DF<1V.IA/L#]AC_
M (*4_L/^,OV?_P!DGX>ZK^WK^RSXQ_:!\5_![X+^&]3\%:C^U'\(O$7QF\3?
M%*^\%^&M,U+0-5\-MXSF\8ZO\2-1\2226.HZ-)I\^OW?B.2XL!;2WH,0 /UG
MHJD+^$C.)![-%*K#V96C#*1T*L 0>" 1BB@#Q?\ :6^#&B_M&? #XZ? 'Q'?
MW.G>'_C=\&OB1\(-?O;38+BU\.?$OPEK/@[Q%)"V3*C2:7JTJ&6-?/AP)+(B
MX!*_YP'_  3[\._M2?\ !L[_ ,%&-9\8_MQ?L_\ C2\_9E^)?AG4OV?_ !M\
M>?A_HFJ^)_ %GX9\0^,?#FN^&OBCX4\2Z-%J$5[J-OK7AW1I]9^'7B"33O&L
M^@ZYJLFE>'[K6++PW;WO^G)?21Q LXBP8R&$C(B2N3LMX)V(9_(D>20D[3&F
MUVD(7(/XR?\ !1/]M3QU\-/&>G_L]?#+1_#\5YXH\-:8/$OB;QCI[:MHDMCX
MNO[FRCT2QL=<$/ARXL+RQM+ZSN[W7(M1TZXBGDTNSTC67.IRZ!\SQ=Q?E7!&
M33SS.)UX89XK!Y;0^K4%B*D\?F52I0P-/D=.HH0G6HR4ZTHI4HKF<XWN_I.%
M.%<]XQSB&3</TZ<\;'"XS,L0ZN(GAJ5++,MITZ^8UYSIX;&591HT:M*3I4<+
MB*U6_+3I2DM/O?\ 9^_:Z_9I_:G^&4/Q?_9\^-?@#XK?#J6S^VW7B7P=X@LK
MNVTC?YDEU!K]A*\.L^%[ZU=9SJ&F^*-.TC5K(QRSWUE!$R.?@#]O[]JWP;XY
M^'.N?LZ_ N2X^,/Q,\=WFF:=>:9X1L;KQ18Z5::5KFG:K=Z;=3:;;SP7VI:N
M]E!I\5GIDMW=Z5O%_J*65E(D[\=\-_\ @BC^R_;^#O%_B+QA:6/A[XQ?%.TO
M)_'GQ(^!_A?X>?!^_P!,O[^9KN^N-+N?!?A>PL[VZMG:*ZM[G5K5X[N=EU0^
M&_#^IBVDTG^>S]L/]HS]NW_@VI_::^#NE6GQDTO]L[]A;X_1^)M4\/\ A;XN
M>$/AOX:^--I9^"]2\,6_B[PM??$SP3X2TS6M2UC0=)\0>%M5\%:S=2IX+OY]
M6UJSTSX?:)<:9KFI7_@YK@N)N-,DA@:57#9+0SW UU4E*:Q&:2RJ=*,L9&AB
M*<_[/PTJF'JQC*%;"5:LE[L'"HIQ/I,EQ^0<*\0T,VH4\RXLS/AO,,)C<)ED
M)99D^23S'"UN;#XEXG%0CG688;!UXJLX5,+DSKP<7%3]QK^G;_@FA^R!XU_9
M_P!-\5>._B78M:>+O&>G6.@:1H0N8)GT+PQITF)X]7>&ZFMI]5U01Z;'^YED
M-I#HWDW)AG=HS^NMHDJHPD7&V=RK97]XA0?O0%9MN]RQVG!4Y& ,&N*^&_B+
M2_%_@WPMXKT-+Y]#\4>'M$\1Z'-?VMS8WDVB:UI-GJ.CM>VM\[ZA%>QZ7<VE
MO>KJ ANVNX9FDM[=2D2=W'*I++SN#+E>68!P=KL%!*HQ5P'8!<JPW9!KZ#A'
MA?*^#>'LNX=R:-2&#R^,_:2JRISJXG$56I3K5YPIPBY\_,XNG"$;.S3T/G.-
MN+,[XWXPSSBOB*T,SSRM"H\)3FJN&P-+#KDAA\+*+DXTX12BU4JU92<;J6K2
M_A0_9-_X*0_L7?\ !.3_ (+N_P#!<+Q'^V7\9?\ A3VD?%;XB_#[0/ $\?P[
M^*_Q'G\0ZMX>GU74-8M4T[X3>!?'>I:>+.TU"SD^TZM:6%K<-.(;6>>=9(T_
M6[XK_P#!U1_P1N\+>%-2UCX:?M >,OCUXNMHXH]"^&7P]^!GQV\.^*M?U22*
M]N+6.UO_ (L_"SP'X-L66[M++3HYK[Q5;J;G5E2_M4MH#.OP#_P3G_9G_9K_
M &G_ /@O!_P7=T?]HOX ? _]H+1_#7C/X7:IX9T?XU_"GP%\4[/P]>:M=:U#
M>ZMH>F>/?#OB"TL+J>U2SCNI5MX'=%B5"[QSQK_3W\.O^"?G[$'P=UJW\1?!
M_P#8V_95^%6M0W6FWIU3X:_L[_!KP+J0O]!NS<:->0W?AOP)HUW'=Z?-+<7>
MGZC%>0W.C7+SSZ-Y4M_=RR_2'S1_/;_P0F_9,_:=U[Q;_P %"_\ @K!^V5X#
MOO@[\2OV]['49_AE\'+^SO-+U'P3\&/.\1ZU*VLZ#J%M8ZM'H<L,/P^\,> -
M,UN?1?$,N@>!-4\3ZK9M%XQTZ2Z_&7_@W&_X)5V__!33X ?\)?\ MG>(?&7B
M;]B3]F_XH>(?"OP@_9JTG7]:\+>'?B!\:O$^G:)XH^*OCSQ^^BZEIVKSZ%HO
MAS4O"7@W09-$U.UN;^S$FG6$^@VNF^,;3QS_ *'GC6-X_!/BN)A'F3PYKWVA
M&!:"1+C2]0>=$,0\] @#L9Y(T,K*TCEY9)"/YG?^#/\ A8?\$@K-AN1Y_P!I
M3XV>8WF,[LT5KX&LDD1G& D*6Q2-%+(A1@OWL4 ?)W[</[/OPR^,_P#P4&_8
M_P#^#?']FZU'[,O[#_\ P@>N?M=?MH^'?@S97.AOX^2:]N=?\-_#F\EU>74K
M\VMU?^"] O=06^UG7O#,6H?$G0_'5_9:WXT^%FAZ=#_0IH__  2"_P""8VB_
M#NW^%UG^P3^R8_@^/2WTIK#6O@5\._$>I2306U[:KJNK>+M;\/ZOXSU+4Y1-
M?/9^*-0\1P^);!I()K?5;?5;#1?[,_#;_@I5JW_#LW_@NS^QW_P57^(]GK=A
M^R'\?_A++^QY^T#XUM=-O-4LOACXY>VUQM#UKQ#-I\.H21:7=6T7@CQ-:6.G
MP7&HZKIGP^\=PZ?;7,P6W/\ 4GX7^-WP@\<?#2S^,7A;XF_#WQ)\(M5T"Y\2
MV?Q/T;QEX?U/X>ZEX8%O(\FJ'QC;:E+X?-I#"(Y]0O+:]:VL9+:YENKBV@NX
M'N0#^1W]A*+QO_P1X_X+K:C_ ,$H='\=>+O$G[%?[:GPYU+X\_LR^"_%VOW.
MJI\'-9BT#XE>)8M,T:Y\2ZYK<^EV7VKX>?%CX9'1S?V^M>*)'^#WB7Q;/K>H
MKK%Q)M^&_P!A+]B0_P#!S=XP_9^/[(/[+;_!"U_X)C:=\1['X,_\,^_"M_A7
M9^-T^*_A:PB\>+\/!X3M/!]KXY32+BYB&OIX??5)8KZ\@NII2L#W6)^SUXFA
M_P""O_\ P<AZ=^VS\%M-D\2_L:_\$VO@Y<?!_3/BN()9?"_Q5^(L]E\4X] 3
MPQK,\=L=0O;GQ?\ %K5/$XGM8;BRL] ^'EA-J5Q;P^)O#KZU]*^*_'7A+X._
M\'9>B7_Q*\0:3X.C^-7_  2ZTOP9\,+GQ#JVGZ9%XZ\4ZI\6'&C>&M&DFN%C
MG\1ZH_@'Q=8:-I4C1:AK=SX?EATRWN[BZLDN@#^A'X.?L;_LD?LS:OJFO_LZ
M?LQ_LW_L[:YXBLK;3_$6K_!/X*_"[X4:CJVG6]RE_#IFI7W@;PAX<NM:TJ*2
MRN;B>VU*1GBA\^:VN+8HS)_.GXS^*G_!IW^Q'XD\4_"CQYH7[#&H^-+;Q%J)
M\;Q:I^SWXW_;)\2:?XLFO9;WQ)IGB'Q(GP^^.<WA26RU2X>VU/0=2\6G3-&U
M>+4](N-'TS4K;4[4_J[_ ,%A_C'XL\/_ /!.G]OU/V=_'HM_CS\/OV>O%EW+
MIG@?Q7:S?$+P3IGB"TBT_6/$4NF:)<WNO>%YM+\&ZAKVN:?J,EE:3K<6]IJM
MM>:>VCQZWI/RW_P09_9._P"">ES_ ,$O?V5/'?P/^%'P&^(&K>+?A#X,U3XT
M>,KOP=X<\8^-]0^.VH>']+O_ (O^'/B%XBUC3+S6UO?#'CJYU70[#P]<Q)9>
M%] T_1M*T:;4O#UEINLZD ?@X?VD?^":_P $?^"T?_!,3XV?\$>/BM\-M-^%
M'[8?CG7?V?/VK?@A\$[?Q3X&\"1WWB;7O"7@WP)XG\7?!7Q#%X3LOA]]OO\
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M)F>)O -S\,=>_8-_9$3PUJ=I_95O_8GP$^&7A+Q#92LK3#4/#GBGPAX6\/\
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MQ9X"\/:-JNCR:=="RU :;=37_AC5!I\MOXET2^M[J[T[5/P+_P""9OQ+T?\
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M=7_F/_M2;+A4WMU;8H7<3M &!16@LTC*&%H^& (RR X(R,@X(/J" 1T(!HH
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ML4_LW_L%?"-?@3^RO\/?^%8_"M/$VN^,5\+_ /"6>.O&I'B3Q+]C.MZBVO\
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MS\T$8RG5P]-3A!5,12IU)S3:C2ES\[C9JTE:/*W=?%[K=D?GA^QS_P $J/V
MOV ;CQA??LH_ /1_A-<_$'0;'PIXMO%\=?%7QO?ZUX=AGO\ 61H=UJ/Q/\:>
M-;F*SGNKI)IHK3^S[IQ;V4LMT8=-T+3='^5?&O\ P;S?\$@?&/C[7_BA?_LP
M/X)\0^,KG4-2\8V_PG^,WQS^#/A?Q/\ VU:I+/9/X0^&?Q*\.>&_#VCB59F;
M2O!VG^"]+RQ6\L[N%U+]O\?M"_;B^!W@1?'#?MG_ /"4VB>)/!OAF'06^!'P
M\T<*WBG6M+\,RW"Z])/JFHW"Z8UY'=)'/;Q"9IIF4EVDKJ?C[8?M*? S]E;X
MX>,O&7[2=W\1?$SP^")?"^K6'P_\+?#:[\(VD?B:WM=4M;?4M -S#>-XFTJX
MBTRXU+7;:Q2(6<<<4RRF-3\7CN,X82>?TG@:].ID60T\WJRK0?LW5F\/^XER
MM-*2JU.3X7[FLME+Z_"\)5L3'(:D,?A*D<^SZIE%"--S=10@ZT95DG'E?):C
MS-R=W4LH6YG#?LO^".7_  36TNY_9@GT+]EKP;X2N?V-_'-Y\3?@,/ GB'QI
M\.CX8^)4^K_#_5;_ ,;>)4\&Z[X8M_B[XEOKCX7_  _635?BO9>+)+FW\)65
MI=W$UE<SB;Q7_@IS_P %"_VL/V!OB=\(?%OA7]@GXB?M5_L57OA+7[C]I+XF
M?""_M->^)GP^UN]URQLM#LO"7@)Y+E[O1/#7A2TUW5/$3Z]IWAC1/'M[K/A6
MQM_B-X$/A7Q%_P ))]O>!/VT?@MXS\>Z/\.].UO6[?7->N+FR\/ZEJWA#Q/H
M_A3QGJEG%/)J.G>%]?US1K*'6IK2.W>-[@S1_P!H3Q3-IOVFU:VEE[WXQ?M/
M?"7X*:MI^@>)=2U^_P#$EY8RZK;^%O!GAW7_ !EK]KI44MS:7NKW^F^';.\G
MTK1X)+29?M^H!K6:6*6.VAFEC85[U'B3),12E6ABU3A'$87#7JN*?ML3A5B8
MQ2TDW95$M'=0N>'4R+.<-*-*M@:F(KRHXC$JGA832="ABIT'43?M%RQ3HJI)
MN*523BU%N,7_ #-V/_!S#_P1R\-1W/B#X%_LR_&GQ+^T!K1T]M,^&W@C]E_P
MGX>^*VO^([.!;:P\-:OKUKXG32XY+6"7^Q=6O-$UWQ0^EV#ZK8^%_#7BN,V^
MFZI]-?\ !$[]G#]I[XH_M._M9?\ !8G]M;X92_!;XW?M>Z5X9^%WP9^!6IV6
MH6'B#X/_ +./A1?"#-'XKCU"UL_$/]K>*I?!7@N#3;#7M$T6]W^"K[Q/?:1X
M:M_%]EX<TC]S8/VA?A'>?".X^.&F^*;;4OAG8P)/J/B:QM;ZXU2Q'VZ"PF)T
M:'PY)K4>KP7]Y;VVIZ=>:?8S:? T-TS(6D9>?L/VN_@A>:=\1]<@UW4KOP_\
M*UT2#Q=XFA\,>(-6\/\ VG7Y[RTTK3=$U.UL)[_Q7?RS64GGIX>BUV*RWP-=
M7,<=Q;!])<0Y#)2J4LQHNDL!/,U*4XNV#YU0IU7)6CRO$/D;6CTBFI7,HY1G
MEXTZF3XRG5>/IY8[QERK&6=:I0Y>12]I["THP^*_O.+BT2?M3?L2_LM_MP>
M'^&'[4WP6\'?&#P,WVLZ?IGB/3C;:IX>O;K[--)J7A3Q5H]QI_CCP/JY6U@M
M;S6/ GBSPW?:H3+%=M-:B,K^9/PN_P"#:G_@C)\(_',/C_1?V0-,\0ZM8ZQ:
M:YI6E?$SXE?%7XA>"]*>-BKZ7=^!?%GC;5/!WB;1(_-69=%\<:7XOT^[NK=)
M+V.X*6QK].OA7^V%\%/B[XL7P!X;U'Q-I'B^:RN]3T_P_P"+_"'B/P;JVH:=
M9+;FYNM'L]>TG3VO;=!.LAA#_P!J)&+BYELTM(O.KG_%_P"W'\"O!FM^)/#<
MVJZ]K_BWPMKVH>&M5\&^$/"7B?Q/XJ?4=(MK"]U1SI>G:)=L-.T^UU2UF.JJ
MQT^[G,]E975Q>6=W;Q9?ZR9)2HTIU\RPZJ3KRP<HP>D<7"G"M*G9MM*-*I";
M3NTI)O0TED>>.==PRZLJ-"A2QTJDH2?^PU*SPRJMK1<V(7LXS^"_NO5H^F3X
M)T*3PI-X&^S):^'[O03X<;2]/;4=/MK?0Y; Z=?:58OIM[9'2;1]/'V'3X]"
M;11HUF(;;2Y(8+:WB3PO]C?]BO\ 9A_8!^$<OP)_9/\ AU_PJGX2MXJUKQH/
M"[^+_&WC<#Q-X@ATZUU?4/[>^(/B3Q7XD<WD.D:>/LMSK$D$#0D6\,09@WH'
M@/XX?#?XC>!Y_B9X4\5:7J/@VUM[J34M=:YFL9=);3HXI-4M=>L;Z"TF\/ZA
MI<<L:W^GZK!9W=J@\Z:!(6C:O(O!G[;GP(\>>*K/PCI>MZU8-XA::V\&:YXA
M\*>*="\+^,KBP5WNX_#6O:QHFGZ-JER,E8(K2^FFOFCV6:SR(ZC9YSEE.MA<
M/5S+!NKBZT(4E":2<)1J2=VYRM)<L=7HM4U=JT1RK-:JQ+I9;BVL'*M0Q'-3
MDG'%4J#Q#II\J32I.,W'X^1N=E'4Z#]L/]CW]F_]O#X/7WP"_:A\"GXF?"?4
M=6T;Q-?>$AXH\8>#1=:MX?NGETJ^3Q#X$UOPWXJLI+-I;A533M:LK>[6=H-0
MCO;4F*/B_P!K?]@7]D/]NOP1X*^&'[5/PVD^*7@?X9>--.^(O@W09/&_Q#\&
M1>'O&&BZ/JOA_2=4%_\ #[Q-X2U'61;:+XAU2T6QU^[U72G647%YI\U]->75
MS]":3\3?"&O^-O&GPQTG499_%_@33-"O_$]B+.Y1=/M?$ZW-UHI%W);K9W+7
MD5A>.;>SN;BYM#%_IT-L)8A)Y%\0_P!HWP;H7PZ^-7B[P]J-Q<:E\(]2O?!^
MMLGAW7]273O&:VV@"RLIK*PTNXN]3MI+C6M,,E]I4-[IT$$LLUS>11Q3219U
M,]RZC@:F/GC*%2E"IFD%&B^:<_J4*DZ:2<F]'3M6=K/F7+RF6!RW-<;C</@U
M@IT74P>48NK4JIQIPAF6*JX:34OL1<E2]BY*37O\RG[J*?[37[#/[(W[9OAV
M#PI^T]^S_P##/XT:3811VNF:AXO\.VM[XI\-Q0*BQOX.\9O&WC3P=(SM*;O5
M/"/BGPQJMP(O+:2X$K>=^?\ \)/^#=K_ ((Z?!OXC^'/B;X(_8ZT&_\ $/A:
M^AU;PM#X^^(GQ;^*O@[1;J-Y)I)X_!GQ/\>>-_"FLIJ,UU<7<=OKVE:O9V5Q
M+_:-I%INM6-A=5]9_"O]J'2?B[^R_P")O&H\4ZWX+\;>%O@MI^O_ ! \;77P
MY\3QZ5X0\0ZAX3GNQX@T"TUK1[*W\5V>B75EJUT]EH*:J)W V%DNH6E]GM?C
MKX&^%?P&^'OQ)^(GCZ37]-UCPGX4-OXJ3P[J-MK'Q U76-&LY+.[TKPEI=C=
M:C]LUV1S?KI]M9&6UCDD-S#"MO.XYL!Q'A<:J53GITZ-3AW!9U.<IQA[.6)Q
M%6A43<Y>]3IJGS1II.K-OEC)RT71B,FS+#1KQJ4VZ]#.<5E$H4Z-2HI5\-#V
M_LUR_#.5"4).;;C3;YYQ4&CVWQ#X1\(^+?"&L?#[Q/X;T'Q9X,\0:->>&]>\
M*^+M%T_Q'X<U;0;VU6SO=&\0:1KL.H:7KUC=6:(MY::RNJIJ[S307_DV\I9/
MR9^"'_! ;_@DO^SI\;O#'[1WP9_9.T[P=\7? _BB#Q;X,UY_BC\;-?T?PEXF
MMI;C[#JVA>#O&'Q1\0>&+>VL#<)<VNF+:)I^GPPQ6^CV=K$D>GQ?>/PM_:T^
M$OQ2U75- TJ]UOPWXFT33AK&N>%_B%H6N>"]9L-$95D;6K>P\3Z9I'V[2;=9
M(OMVHVGGPZ6\T,>J/:>?;^;D>"/VT_@OX[\8Z;X'T>^\:VE_XCN GA*_UWX=
M^,=-T+Q>DD!G@.B:C>>'H+>>SO;9#=:=?&6.TU"T9+FSGN898G;>CQ#E-;ZN
MJ&-I8Q5U5O6I?N(PE!1Y8?5ZW[Z;E)N#E%N,>7F;M)(SK91G%)*5; 5,&XQY
MITJK6)<H._+45>@XT::LG+DGS2:T5G%GU>^EZ>SNS:5*Q9F8LMV0K$DDL!]K
M7 ).0-JX!^Z.E%6TF)13Y+)E5.PW.PID [2C.&0KTV, 5Q@@$8HKT_K$>Z_K
MYG%R3[+\3^$W_@O3_P &R_Q9^,OQE\=_MH_L Z+I7B75_B3?:AXS^-7[.2W^
ME^&=1O/'MQ:^1XC^(?PPU+6)XM U.Y\?W^WQ+XV\%ZE?:%?7&MMJ6I:&GC6_
MU.U\,:=S7_!.G_@YU^,W['NE^&OV0?\ @L)\ OC-H'B7P'8:;X:TKXZS^$-=
M\/?%J70++R=!T"Z^-'PM\3_V!K?B/4;0Z;>V-Q\0_!PEU?QG:6$-UJGA?7?%
M5EXE\<>+_P"^26 R2.=JX:-$W@R1MQ]HX=HI5:=%,BE(66)8RTDBS,[!4^&/
MVQ?@EXF^.>CZ#\*[#X1?!/XD>$_$4.H?\)?K_P"T%X4T7XI>#/"<(MGM$FL?
MAQXATO67\5:_J5K<75O:37\BZ=9M';)K"ZAIZPP6\X['PRW#RQ53!8K'I2A2
M6'P<7.LYU6XPJ649_NZ;CS5'96BU[RZZX>C3KU84JN.PV74V[RQ6+A.=&"5F
MXN--J?--74+*7O+6+3TS?V</^"F_[ _[5_@YO'W[/_[57P8\>:6;:#4=6TZ#
MQ39^'/%VA1S6\#";Q3X!\5Q>'O'WA;&Y86/BOPYILWGQ2PJSK"NWR+X^_P#!
M4KX%> K"_P!.^&MX/C!XS:*^M;&PT"2[A\*6U_8Q2W/F:KK9MX6U.WA$+2R1
M>&7U9S"0MRL,<\$C>*_#?_@AS^R5X*\':SH^G6NN>%/$GB&:YN]7\2_#7P[\
M.OAPCWNHR-/>3:1X0M/ FN^$-"@L9I7&DVGV#65M8HH;:*ZAL8K2PL/)_@Y_
MP3E_:V_8'^-?AOQ+\!_B'HG[;G[.WBCQ3INE_$3X2_M*^"_AKX-_:$^'6AZM
MJ$EG)\3/A;^TIX*\/Z!I?B8^#I)M*UV_^$OC7P!%8'1- \02^ O$>F>+O&ES
M:'X?,*/B!G,)K(,;EG#5.O&45BL=AYUL;0I24E-4_:U8X>GB)1:5*JZ,I4YQ
M4H)-7/N,MJ>%F63IXG.*N<<75\)4IUXY1A*4\NR[&5*;;C]8K1A+%SPD96=>
ME"MAZE2$N6-1,^;+3]G[]LC]O7XGS_$KQ7X9U'P]IVO00K+XG\76EUHWASPQ
MH]L(+O2[7P_H.HR6M_?6]A<M>M =.LKISJ-U<_;-ES!=)%_2;\"OA+X=^"_P
MT\,?#OPQ;/#I/AW35MQ+,J"[OM2N7>]U?4;QU \RXO\ 4[F[N0YW%()((-P\
MG:OI6EP+#!"JVLEJN69H) 8FC>7]]*\B(TJ33/.[R7,C2R^;<O*XFD4JU;,(
M8!MQ))<D$[<8VJ/E"]%R"0&^;))/6N#@#PKR?@6>8X^3K9GQ'G%:6(S//\57
M>(Q6)G-N52"G)6A3FW\,5;EBDG9'I\?>+^?^(^6</Y#B(83*>%>$OK,.&^',
MOPTL+AL!2Q2C":GS2E5Q,HQA'EJ8B52I!W?-S2DV] 0J@\$#FG445^HI**LC
M\N"BBBF 4444 %03<$$)N) !Z?=R>,'W.>_T]9Z:RY'3GM^?Y5G551P:I-*=
MXZO:U[M?.R7WC7+=<RND[Z]'JD_E=GY_?\%$"T7[/<<H1E6/XH_"=VV@LVT?
M$7PW(6 0%F"QQ2O(0#Y:(&DP"N:7_!1V(3?L:?%FVRK%H?A^L4;!'@EGM_'G
MA@((P"?MXBNI()IK>/S8/*M9MY0>9G[[N-/6XP7B1V^3&_RB!Y,BW$1(EBN8
MR5FC1HR(=\; NKYVXJS:4LT;02A3%*S2NCI;3;O,E>YFBN/M$%S#*#<SO+$(
M[9%0P1D,IQN^9Q_#BQ\L_G6K*#XBP6&P&-YG!TZ5#"M.'U:\>:%2I9<[JSJQ
M=G:*O8]S!YY5P,.'J=.%-0X:Q^)S' R:FYUL1B6FUBO?49TZ;5Z:IQI2B]7*
M32M^='[9^C:5:>&?V1'T72;*&WTG]K7X _8X[2SACM++3TEUB6^MS=Z6LDFG
MVUU''=12W-H7TV5K<1W=QY4BL_S3\7+G7/@]^U[\6O%WCGX]^(?@)X0^)FA>
M ]2\%>/;;P/X7\8:!XDC\+:"NC:UX(N]=UC1M6/A+4KC5[>35F@M)5MKRTMH
MII;83ZBAU#]J&T6WD.Z>&.=H98;FVEGCMYYX[NR61+6Y2*:"2T2YWS7%REW$
M+>56E2-E01Y#9M'ANT/VF!9'4IY)N)&GV;46-W(A-HT;RJ@+I%<&')+!02ZG
MQ\=P3+$XG#XO#8O"PJX?%X7%QPEI+!5)X;!5\#%U:<)QJRY:->51<M6+5:,9
M7Y$X/T,%Q9]3HXBA7=>I1Q.$QF#J5Z+B\;"&-QN'QT_93K4Z]**]MAHTY1E1
ME&5"=12O-QF?B->^'-&LOV&?VM?%?A+QWXP^(.F_$C5CK;^*O''A"'P5!K6J
MQ'PSI>K^)_"FDZ1H^C+=:=KDJ:3<O>II$!N!I4EOAI+5Z^K/VH;C7_@?^SCX
M"TKX36(\%^$K/Q;X%\+^,O%7A_1X-2G^'WPTOX[F'Q%XVTS3K>SU&/5+W29+
M+3I'N[FUNK@C53<6<=Q+!<K#^B4ND1-:FSCMT6U91 8U^SA!:S%(KJ!UG@GC
MDA,<CS"-HWD>2,H;A1*H1SV)(\N0 J8A&9&9F)Q#Y):X2*,1W9<J7*2>3&0^
M1%')O=LEP!2IY1B<#'$4%B/]6/[ I5(.2G[&CF+S:%:3Y^9XB>(<J-2:<82P
M[4>13]\UGQSB9YG0QM58O$4%Q'+/OJN(5&5">)K99#*8T9TX4(1>'IT:4*].
M/(Y4\1%24O91Y'^+_@SQ-\+-7_:P_9?/PX^/7Q9^.46G:WX^EU_4?%^ICQ%X
M5T1KOX/>,V1HM6@\-Z5%;W5U>/%.UC)JKFV%C;6ZVZRR6RS:GP@^/OP@^"7Q
MX_:QG^*,R>"XO$'QIFM=(^)$VAZW+H>H6EGI6D1ZEX/3Q!96[C2'TJ7[/XG%
ME<O%_:HU:5;>XNY7@MJ_7J#1K>V6$0686-09!#!&862>,N$&9+VYMTAFBFN(
MVAB@<;)G+,GW3Y5\.O@5X8^'.N_$W7-,EU'4I_BEXZF\=:_'J_\ 9,UO:ZE+
MIVE:(8M+AL=$T^2&S_L[0M/N&2>YFE-S-.69B *\FMP5F,)9=B8?V74JXS'Y
MCFF84ZM.O*AA\3C<KP>6*&%BL0IPI4J>$A5I*K.<H8B=2;G*#4%Z<N+\%B\#
MF.6U5F=*C_8^ R6$Z%6A3Q,Z."SJIG<*DZCPSHNI4J5'0JI473J891I\JG:J
MORVC^'7CCXR_L[_MP^*?AMHNLZ'X?^.7B[3/$?PKTA+1M.U7QKX<\&V^C6/B
MK6].T.[N;W3U7XEKIFJ2Z:E[:6EQ<&YCBURUMWB(7CM/U3P3\8T^#?PZUC]J
M[XL>.]4M/%?@*XB^#.B? /X?Z)XE\#ZKH%_IRW\U]<:)\,++4?!FF>'(X[\Z
MA?7>I6T6J6>4TN:^N#)$?W@MK&1 4,2-$7/EJR0&*U +C;!'#;V1B#(P(E_?
M2[F*NQ6-6.?#H,$-_+?FSMH;IE?9+"+)Y>=P"&6/3+2[G3(WLEU?2+EB.<8'
M<O#^KA\7A\92Q>&KU56C5E'$.<J<'>3<:<:<Z;4%SOEBY.UHW>EWS2X^EB:>
M+A+ U:'-F.*S.FZ44I*KB,IH9/*G*56%64Z2P^%IU8M6K?6:E:;J2IRC27YI
M:_\ &;PC^S3^V-\8M;^,-U?^%/"OQ5^'?PUN?!'BN73-1O\ 2=8U;P%9>(-,
MUK1+.33;;4)KC6YFU0W+Z8T,5XZ&%XK203PRSP?LV:R?B5\-/VZ/$FEZ3J]D
MWC'XM_$^YT#3-3TJXBU![(?"CPE%X<O(+"X@2</JD/\ 8NKV]O+"EY;7%Z;>
MY@@NH9X8OTXN-*6Y 2ZMX940ILVY$K)EFG4F6.:*))\JGV:".,*(MYO"9%6&
M>RTN"V@FCCCCC,C;A^[3:CE<&9(FD8^;Y12W=VGD#+;Q[5" HW1#@JOAJT,/
M#%X2>%E1S9\M13E)5<SI<E5752*2IN4G2O!M?:<CCCQC@JN7UZ<<'CH9C4P^
M2X*552C&FL/DN.CC:52-/V+DJU64(TZK594^2_)33]X_*/P%\5_ WCW_ ()V
M?$GP3X3U5]1\5_"_]E+6_#OCS2I=*U&"\\/:[:_#CQ#I+IJWGV5NMS>/<>'=
M6G,%H]U-&&@E9%CO;)[BKJMWI_@/P?\ \$\OCGXNBN9/A1\._A':Z#XSN[72
MK[7T\%ZQXI^%_A.Q\,^.+O2K2VO!-8Z3<V&OZ+<7,5K=7^G3>)5NTA6&SN)(
M?UAB\/6:K<QFUM&ANWD6=6MM.Q-"]M/ WG1V]E9HSLMS/$5G%\FR5\YWD1V5
MTF%HVBN(A/'/YAN(9C 86$K,T<3QPP8G2UC*6L:,T,?DPQG:TFZ1JEP3B*F'
MA2K8C S='+LORRC!>UA!4<NQ4\7AZ\E"K!RKJI-J=W[&<;+V/5Q2XM<*N,DL
M+B*<<=G6:YU7<?>FJN;Y7'*\7A:4JBJ*.&5&*J4%.,ZU.LY2=9IKE^,?#?[3
M7P,^+E]XVTKP+'J?Q L_#?@+5=<\4:YH7A36M1T.WMD:QN$\$6'B0V2W&LZQ
MJ<@.K7VE6.GZA:SV?V*SU&1$%G;M\*_"/XD:=\/_ (F?!7X>?LS?&WQ)\:_A
M_K?CBWTSQ!\!/'?@A;KQ%\)?!\UK>&3Q!I7B:7PQH.J^&D\">=':R:?K\F^X
MT]8K+1Y=1CM2D?[8P:%:VJK'% @CWQW'EQEUACE@8D+# ]P[1B=&5&C%P;5?
M)#"%&D<M';Z#;VM[)=16ULLKM(3,([)99%<F0RRBVTVRF=W9S 8GNWC\J&)V
MD:1GSOB.%L?BY9=4KU,OGB,O<:='%8:G*ABHX>3BJM-JG6CAYPE&$5-U,/*;
MLG&497;RPN?X+!4L9AJ-/,/J>+YIU,-BZL*^'G749JE4DZF'E7ISA*<G3^KU
MZ2BFXR4X^Z9Q-O$3$='%P8SY9N&NOFG*?*9FR2=TI&\Y).6Y)HKIA:K@8LR!
MC@+*44#L B.40 <!5)51PI( -%?9++6DE[5:)+>ET2777IUU/!>+PKNVJEWJ
M]9==>BMUZ:=M#7JK/]\?[H_F:**[X?%\F<\4F[-)K71I-?<TT5BS8/S-PY Y
M/3TZ]*C)).223ZDG/YT45SYKIA--/W]+;YG:DELDO1)?DD7XB3$V23ASC/..
M1TI\71O]\_R%%%/#?[M#U_4\RI_O7RG^2):***T- HHHH **** "BBB@B?P_
M-!4,@!(R >.X]S117/B?X3_Q1_-D0^+Y,9@>@_(5*@&#P.OH/0445PPTEIIH
MS8CIDGW&^G]:**JE_$CZK\T7#=?XX?J.B^Y']?\ XFFIU?\ WS_(445T2WJ>
M4E;R]][=BX_'5]8_J/HHHI0WE_@G^109/K28!Z@'\***X*G\:/\ CB);/U?Z
M"X Z#%)@'J ?PHHKJJ?QJ?\ @E_Z3$?7Y?JPP/0?D*<@&X<#OV'I1173A_XG
;_;D_R1AB/X?_ &_#\V#=3]3_ #HHHKI$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45482239507904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTAGONIST THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001377121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0505495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7707 Gateway Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94560-1160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">474-0170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTGX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ (8IK6I>*NQS     $P(   L
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MU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ (8IK6B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ (8IK6@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  ABFM:UUD[+^T    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( "&*:UJJQ"(6,P$  "("   /
M  "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ABFM:)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  ABFM:99!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm258886d1_8ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protagonist-inc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptgx-20250308.xsd</File>
    <File>ptgx-20250308_lab.xml</File>
    <File>ptgx-20250308_pre.xml</File>
    <File doctype="8-K/A" isOnlyDei="true" isUsgaap="true" original="tm258886d1_8ka.htm">tm258886d1_8ka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm258886d1_8ka.htm": {
   "nsprefix": "ptgx",
   "nsuri": "http://protagonist-inc.com/20250308",
   "dts": {
    "schema": {
     "local": [
      "ptgx-20250308.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ptgx-20250308_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgx-20250308_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm258886d1_8ka.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://protagonist-inc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm258886d1_8ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm258886d1_8ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://protagonist-inc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-25-022615-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-022615-xbrl.zip
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MG-Z39\:[\&G+7%-C,ZG#TM0$Q8C%&(A&J46EV!,1_]B*,W;"TWTO%(;2-1>
M51T-3184'79O(""UW"\C2XYIEL@!K!<24^K\= ,P:YQZ:+J@. ',P:<DM=XO
M*8M'DJ;R?@"F_0.*3>R:%MBPSHNI#(H8T![(3!&!JI!PL+E\D:MSL4P:V-B&
MWB<\ANTN?FIQL CI#@=25(0A&>>)I,9MB!Z&#*5K>@"K.C>:+"AB[-Y 5DHY
M*O3^(;FD\2!$:IT?0#2;=CPJ48!PM)WUH2'4/L&X2K((IZ67*[$MZVB>1>L:
M$-"N#HDA# H4R!T(2QF@F"E"O +S+X+Y,%P:2C^P&%;MJ-2R $'1O?5A(O5>
M()EM.6^YAF<<6.KLIFR/V?K^+* + I0><\9=VU+> L73#'1)\R3?R^?I;K:;
M%>&6QID25VQ YA03>GD0+ "F= 9*&9(Z5 J]]+RZ2T!S^1 CV!Q=YI8 N\DV
M!6U-0"18C0$T'+3%,Z5>B)B)D8GC=$YCLON%[,%V&3JW3  VVU!HHH"HL#L#
ML*C$J% C(?<"QAU/-ICO%TG4,U680K=H0$;;;.BJ@.  K %T5&JTF,]\SB1+
MO)O' M3D(2F?!^^A!-2[A:7'=IL90!P0.MT. 8)$$&I'^01I3B/&GUGC<8<9
MVXH!<#]C,;Q"Z8ER"]6@)K31Z@P)"+ A/@',6J$?RF=2$)/O\105(%F#%^(N
MXE@<J*SZYSJAY!ALOU7KEJX.NVVF+,* 2(+= ?Q4R@_J Y(QZ):& LWT#4V=
M^H=F.A2::=#03-\#S?*5!0+-R1N:>N(?FI.AT)P$#<W)NZ 1'>]UK)F)C[=\
MR5YM#V>#2B_(F%:MP!QDX>%B>.N#10;(]8P,\8E)L;"ZY7><O20T@I?,D-P+
M,(!I*S6:-CQT[ ;[^*D7Q"K.ZUA3+LI[OR1*YF>4:9NT#S&E)CQ(VL9Z!Y=2
M[1.).Y;E./UW\MQY(FX7>\'#:M@*24L9'BHV>WW E#%(!/DXL:YPE3<TK*^2
M:>7N7@&VV#J\ MPH# ("FR/S%>#RZDDI<MW-DE%.,# BM(N==;+%5-W'C;(P
MNM@T9/1P\;T6&A]?9)G=);U[9!1^0,"4N.IIR)SJ;;T\B!X'3.F]7LA0H?-T
M-5YFF,CLPW>CS-G,KMNI)W)5$$3OZFZ,:5J5.^[-WWB2BSW/V&:SI=5='MMS
M@X#.52]WVE0];A4%T?M=SG02*BUJBQUCL6!I$B5Y0M>_BI-/GF!;JVPB5T#
M!A4-IB((%$!;.@<'(5)*QQ#<<2(A)*(CBI< 96(A?OOP8)WMN\2NH.@WK."
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MEZ%F!6@EGQ&KJD"_RTI048OM]\N;FZ[%)[%9;1)_K7!&Q);_ E!+ P04
M"  ABFM:-_#.>%T'  #C5P  %0   '!T9W@M,C R-3 S,#A?<')E+GAM;,V<
M37/;-A"&[YWI?V#5LRQ+:MK8L=NQ%2NCB1.[EI.TO60@$I(P!@$- %K2OR]
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MM6WH*7Q3!"@.C0_J&X7 &"K"=-$YTG5K#[BWU1;?N%_NC:SVR/]02P,$%
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M=2Q($G^O**"2REB?[B2C5#:D+"Q3!\1/V$ M!GP/\CY@L38?DUA)C%RP.,_
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MZC4 J:G4NI9*8A)".RVFN(=RJ$BEV,*$5+EF$)6C7:E<=) CTR OAIP;Z^G
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M "%.:A(<TG#J3^'N1-+).B#@B]\VW/6XM7]>::OCXFV#';A1L69-<+S/OXF
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M*K2LRTB )2]M#1G#ONL@9I^V.P1<L>S#6NNCY2,@)G 3CCGX1Z:[U\'[2]C
MF1R**U^"*7&-$2VEK_Y'AW4[7;;7V6;=[3=O],7RF(4?X#A_PZ(S!3K*O%IZ
MU$\5U*L1$@9M^<]!.R\.?Y/X*ZRW!\_"PQ]BLK!:1R>?UZ\>UD:._]&IUW8W
M-]EV&W#2WNF -Y&QCB:SD_,^_H71,JI  35Z9$/4LX1X;7;/<?-_0S4!?RO!
MG:>+N47*]C(/A6>%\3+UNKE  = UT_"UN_WR1>5EHW7IY1F56\6-JRU04YA_
M74U16>&:(;&NX9R&_^P]&.]Q%(D,[=Y+1LUG*_DFS!;T;0[I,P8I+G0LN%[K
MHZUZY221WB]+(IF6")<FD]0H#DKVW8.2GYS"ABOS/=*9$RUOBR_\]FWJT'[:
MPT:T=(("-E,<,FZPXS@? %[ \L7ZF M]RL@[*L\>NPT=^FCO-]E9Y5-TMD;&
M]OK7!O3KGOE"7;WV[SL[;]J[&_93=:M]I0Z3"S.?JFNR3S0/)?[6R4ZZHZY!
M.WVL#S: 7MX#S/(XTYA"='8E)PDF%D\:+CFSRP8[ <].1$/D37;VH6')F]JK
MEND/]PM."S[&A+3: ^$ 'K3&H"XFO3[]I>?UCE]E>%YV?^,M)7)<5Y,RT"*4
M1: #)\%@ IY[T*GKLM;'- :V;9Q-)@^(*R_6,-M-C.LU!>6:_CO);<$DN(<8
M7>HEJ0Q!XM&'4MO_TV0?@3*))@MJ;+(@EHB%9J?=V6E];7[E/&CBX\WV%ES;
M L>^1[$?&/8!:=-BLS^.-3H_@IPX;K)?XQO-V-_[+A75T7U337:"^;  ?/A?
MZ=0$^-S77(;4%(EG;XT _W(XSK)$O6VU,/DAS"OZG 6JQU81A6Z%=.C#PUA(
M:QS?>+ :+X$[9!W=>C0K:E.8R,"I7GM(0%GN6E9ET607U0" \V#YY5EE"QBL
M^+5U!8S[:0RO3[ V-:$FLF5A7Q66S(4AI\W?R%00_-[L=3IOMEIN6JF8VG.F
M]N*A]S7Z2E-[>FK/3NVY4S\2&1;"RS9^TA66S5%\#;LO.\86X*)2$-M\R,35
MJ2W1??I../7KCB[: %5LO]23,J>91K. /%5]2+#HYE;;\K-N"[][VG)??#0H
MWA>,<[T3*(4U#\,Y@)5]KF=:)2QIDI#P<%+$S<J."21>$8W%9Y*IA<)KMY_$
M!O: 6X"0=O=/(@1?? Q\V"+\)=BX<K%A3^M8C("A5VEGX6+D=\3()^=8Y!*[
M;9Z.=1<"%VQSX"(::3E/_R?8E)-W*"SL&JFR*.71MW>@OQZ'M'\ DJ6Y2[3]
MIR!9?J3>]FM8("1TXX95@6N>?B3P6;EP;BO4RJV1<TZ7 92Z$K(DH$+Q@(B=
MT3QEDX(X';6HT;CG-"YXG&VMN*_R*M8C@%9$A0V@7ZI6JYO#! /@NJ7*EQ]K
M?ZMN<([U5\:<%NVMYN-LZ'JU_6 $T'2$<MK<KXHOC &2Y5@29.N1,+;B_GZ5
MHS$[U0>5KZ3.FU81-F,K5S>(!WX]?>C6PXHBU:J:PK#$Y&&WN2"4@;Z?\?7(
M!76==I32^L, W4:]ECI1 M-]Q"M[DC7 -U+"L\VV"Z.%2MH62OA*YZ<5S+VW
M[,/EY_/^Z<EEO=;1AGOQ)<'?CXZI[62#?<S#*=OT=A\">A9\E_S_^,V4_>YZ
MR0S (,IC@T4E<'%^D&J4B^.: -VB.P838,EC.0'/LUAWSI@YAC*(Z6-J""2J
MA#2.V>GA29Z"GWJ*[\3A0>L4J*G;[NRR#V*PS[9V7W?!V0:=98)*W>[>@X#%
MPJ4/R&='!52J@:VW.B-*97FZBE)7PSJ;KAQF+8Z<%ILUVXQ'TV*G7;W3SN8V
M;;73Z9JM=KI;#R 'K4%S@846*>M56>>BPCH5FG>LF5,\-X8N)6BU-,9B._N=
M$%.<&P?3B./OE_8X[V_Z*QL79<L?6&4^85<</W2BM*GI?GMJ>2S09N9MOZQN
MH^ JUM$FV0QK@6_UF^&MSWX68Z5MI^-U'@"\%KJV^GWFH.",IVX+C"BC2[UG
M]4%34\!<G!E<Z>"BAMJR$[.,JN>MW-)?RR':-J1=<#NZM,40U0+4Q6+OU*7X
M]_&-"-FQ:?ER1_@ S'J*&Y  \71.NT6U 9X!CVI]U>#Q-'@\A(Y70,<KH.,9
MZ'A<IPQ+Z'@%=(Q2=J(3SO>/<&C?@\U1K =AXTD7-IZ%C5>"QD/0> 5HBK<+
MT&"@PQ4&W@!!X]EN.(]D?M_^6/2H<IK'"27!!@.+_QD*G#F+7=!,^1F@V:BI
M6]S'JR?72WA_QPI+(W%3!J/PEY*,EF+="5#9#2'69HC&4N% ;ZC =+$AS]F0
MH<&9#1$MA$A)SH:\S79G<VMSI]MICK-)^'@4\6,D<6G*RHJ/W%4^#&9.LNAO
M6E=/,NAJ=6M.517KPF]VV5C176)D9<2;:CC/+MLSR_9PV1Y9B%Z'L.<NVS/+
M1@0Z<D'<)1B*Z";@=[>[V=[<>VS\/@C/%_B>^S N8*TX7^PHXNJ9]1+Q2[_1
M5L0&7U^<PS/;&[J/Z@+/<NW\7U"%V5Q)'8!;31S= 9(*5DBG0"@%@=#F2O((
MOTL5"1+.-I[@*W;FW?W!,:"C-SM;G=V./9SQ..3TE]33;3L?$3_#'K7/Y77+
MR^NV_V1YW>/5NK7>?S[^!]6H_-K_=';X_U!+ P04    "  ABFM:ON43)3$9
M   ]=   %0   '1M,C4X.#@V9#%?97@Y.2TR+FAT;>U=ZU,;1[;_KBK]#[U4
MQ8%:C4#"^ 5F%P/>D&#,!9S4?KK5FFE)'6:F)_, *W_]_9W3/2])>,$K)_C&
ME,N@>72?/N]7M_9^N'IWNM_M[/UP?'"$WX)^]JY.KDZ/]_<V[6_<W72W]]Z\
M/_JWN+SZ]^GQZ[6QB?-78K"5Y.)*1RH39^I67)A(QCU[H2<N5:K':W@1KYX_
M]+U=$<ETHN-7@A[=VA6Y^IA[,M037$KU9)JO[3^)1UFRN[=YOG2.D0F#%4VT
M]V;_^.-4CW0N7K[L#_<VW^S_,;.6*[Q[OA5-=?+N7^+RXO#U6AX-=UZ\>/$L
M&/RO^OCRI3?4T61K:]#_-9FLB8/3J]=K:U\8ED]3]<%SK&Y +S<)#UI=&)D\
M-Y&[UER*K^)<I4S"\]3D<F)BG>7B0B4FS3-Q;C*=ZQO5[5R91)SJ6.%65H2X
M-4Y-),ZG,E-B.!*7>1',A!F+$]_DJ;G6<2K%Y=3<ZGB"47),HV4H<B.N4AEG
M8Y-&(I\J?%(RCW!7G,M4!GH2"=S#AUSC8B9N=3X5'T)?I=+"<6A"0)2ME-/^
M7,R?[!^&.M8^T).J+#$Q,(K58JU Y[/M_LYW0L:!\.N'(IUEVL3\%.%\>ZL_
MQ$/^5*L;%0B9BU^4NA:#H44?X7D*EE4@;& RU1.W4^U/A8_%Z;C &R"+CI+4
MW"@\G)IB,K4C#%_L;9X\1CPO%<L&1@_"D%:B%"\X$Y'*&0U)JC' 3*@X2(P&
MUYEQM^,OH+_&8,^B4(JQO#&I'(5*9'*L\AF&,F,=JJ\405?@!D4+9EG6L2@J
M&0-?L(B)4:%A(DS<[600:<AQ('-I 4P5C17., (I"A78RR2ZC.90_E;@5V92
M+3.=V;M666S;#T#?))71(T7?HARSSG]%&%T4;&#T[?NSJ^9DWEA&.IR]^D_3
M\;.9_EU9Z%@1GQW_<G#Q4P^Z#G0;]WMV4>]DZD_MGX.MGAAN#7?LIR=Q(+/I
M;M,"$S0M?0YRIS)11:[]S(UW$OM]L?XD#'XKS&[CV2<I7Q&.E.Z!0Q,E,IZY
MFQNM]8ZD?SV!UH@##ZQCTE>D7W)54X/!R4T@9]V.C&,\Z4/I),ZV0/LD(5F6
MM&E9#LZN?CA^YWTX[$'X*C.3E69&-\S,^H]G/WK#P6![H\<@CW6*)>OX!@I/
M3\#3)B;3 [(I<"H6)L-N)U%)K@/2=Q#V3(7*)UC T:/0^-<9#W1RZ@VW!?%Z
MDINT1V(B P:1E4)D A(9>@D*-(/N3>EOR2,M$ZCU#X<;?:*%6P<4<%#X@*G;
M&<U$BP89H3FC-T,Y,BDO0B0RS6,%0'XTTS@SL:._C)+=\E*/59T&B$M4G5C0
M='N7'\[WY=XF_<+R0!XHSB9N27T*(FZ2"74CPP+K#?KB( BTQ6LXLTBW*PI4
MA&%SPDIML8"32,D8GL"X"$6@QV,@"BR0"6 L*S)2%[X:&<+OM9H!DX08P-[M
ME,!G<] ["\C@CRSX/9'-(M I J[\AI$DVXEA3.:;!#><G6.7HU;S_4>H@]R
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M4$L! A0#%     @ (8IK6J+YYTXO P  ^ L  !$              ( !
M '!T9W@M,C R-3 S,#@N>'-D4$L! A0#%     @ (8IK6N!M.\?^"@  @(8
M !4              ( !7@,  '!T9W@M,C R-3 S,#A?;&%B+GAM;%!+ 0(4
M Q0    ( "&*:UHW\,YX70<  .-7   5              "  8\.  !P=&=X
M+3(P,C4P,S X7W!R92YX;6Q02P$"% ,4    "  ABFM:U\&I/;44  "\=0
M$@              @ $?%@  =&TR-3@X.#9D,5\X:V$N:'1M4$L! A0#%
M  @ (8IK6H%+UOMX(   \)D  !4              ( !!"L  '1M,C4X.#@V
M9#%?97@Y.2TQ+FAT;5!+ 0(4 Q0    ( "&*:UJ^Y1,E,1D  #UT   5
M          "  :]+  !T;3(U.#@X-F0Q7V5X.3DM,BYH=&U02P4&      8
,!@"+ 0  $V4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>tm258886d1_8ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptgx-20250308.xsd" xlink:type="simple"/>
    <context id="AsOf2025-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377121</identifier>
        </entity>
        <period>
            <startDate>2025-03-08</startDate>
            <endDate>2025-03-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-03-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-03-08" id="Fact000004">0001377121</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-03-08" id="Fact000009">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-03-08" id="Fact000010">2025-03-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-03-08" id="Fact000011">PROTAGONIST THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-03-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-03-08" id="Fact000013">001-37852</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-03-08" id="Fact000014">98-0505495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-03-08" id="Fact000015">7707 Gateway Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-03-08" id="Fact000016">Suite 140</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-03-08" id="Fact000017">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-03-08" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-03-08" id="Fact000019">94560-1160</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-03-08" id="Fact000020">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-03-08" id="Fact000021">474-0170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-03-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-03-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-03-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-03-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-03-08" id="Fact000026">Common Stock, par value $0.00001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-03-08" id="Fact000027">PTGX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-03-08" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-03-08" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
